Key result
Higher CCTA-derived V/M ratio linked to ~10% lower ischemic event risk per mm³/g in T2DM.
Why the study?
The study aimed to evaluate whether CCTA-derived coronary volume to left ventricular mass ratio has incremental prognostic value for myocardial ischemic events across obstructive and non-obstructive CAD in patients with T2DM.
Does CCTA-derived coronary volume to left ventricular mass ratio (V/M) predict myocardial ischemic events in patients with type 2 diabetes mellitus?
Cohort (n=306)
No
Does CCTA-derived coronary volume to left ventricular mass ratio (V/M) predict myocardial ischemic events in patients with type 2 diabetes mellitus?
CCTA-derived V/M provides incremental prognostic value beyond traditional CCTA parameters for predicting myocardial ischemic events in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Supports improved ischemic risk stratification in T2DM with CCTA; extends beyond traditional parameters but should not yet change practice.
Coronary volume to left ventricular mass ratio (V/M) derived from coronary computed tomography angiography (CCTA) may refine risk stratification for myocardial ischemic events in type 2 diabetes mellitus (T2DM). We aimed to evaluate its incremental prognostic value for myocardial ischemic events across obstructive and non-obstructive coronary artery disease (CAD). This retrospective study included 306 patients with T2DM (59.1% male; mean age 62.3 ± 10.6 years), with no prior history of myocardial infarction (MI) or coronary revascularization, who underwent CCTA between January 2018 and 2019. CCTA parameters included luminal diameter stenosis, total plaque volume, computed tomography-derived fractional flow reserve (CT-FFR), and V/M. The composite endpoints encompassed all-cause mortality, nonfatal MI, unstable angina hospitalization, and late revascularization. Multivariable Cox proportional hazards regression models were employed to assess the independent prognostic value of V/M (per 1 mm³/g increment) beyond other CCTA parameters. Its incremental predictive value was quantified using the net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Over 3.8-year median follow-up, 107 patients (35%) experienced ischemic events, including 5 deaths, 22 MIs, 62 angina hospitalizations, and 40 revascularizations. Obstructive CAD (hazard ratio [HR] = 1.821, 95% confidence interval [CI] 1.062–3.125; p = 0.029), total plaque volume > 750 mm3 (HR = 5.053, 95% CI 2.777–9.197; p < 0.001), CT-FFR ≤ 0.80 (HR = 1.881, 95% CI 1.063–3.365; p = 0.032), and V/M (HR = 0.899, 95% CI 0.865–0.935; p < 0.001) were identified as independent predictors. Incorporating V/M improved risk stratification (NRI = 0.173, 95% CI: 0.005–0.310, p = 0.044; IDI = 0.057, 95% CI: 0.019–0.112, p < 0.001). Subgroup analyses confirmed consistent prognostic performance of V/M in both obstructive (HR = 0.895, 95% CI 0.855–0.937; p < 0.001) and non-obstructive (HR = 0.887, 95% CI 0.814–0.967; p = 0.006) CAD. CCTA-derived V/M may serve as an independent predictor of myocardial ischemic events in patients with T2DM, particularly in those with non-obstructive CAD, offering incremental prognostic value beyond traditional CCTA parameters.
Wen et al. (2026) conducted a cohort in Type 2 diabetes mellitus with suspected coronary artery disease (n=306). Coronary volume to left ventricular mass ratio (V/M) was evaluated on Composite of nonfatal myocardial infarction, rehospitalization for unstable angina, late revascularization, or all-cause mortality (HR 0.899, 95% CI 0.865-0.935, p=<0.001). CCTA-derived coronary volume to left ventricular mass ratio (V/M) independently predicted myocardial ischemic events in patients with type 2 diabetes mellitus, with a hazard ratio of 0.899 per 1 mm³/g increment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: